Search results
Results from the WOW.Com Content Network
Pfizer announced on Dec. 1 that it was discontinuing phase 3 clinical trials of the twice-daily version due to high rates of adverse side effects. While these were mostly mild, a large percentage ...
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On ...
Pfizer has a once-daily version of the weight-loss pill still in the development. It hopes a change in the drug's release mechanism can reduce side effects, but early data on the new formulation ...
[3] [34] It has been used to treat hirsutism at dosages ranging from 62.5 mg/day to 750 mg/day. [44] A study found that multiple dosages of flutamide significantly reduced hirsutism in women with polycystic ovary syndrome and that there were no significant differences in the effectiveness for dosages of 125 mg/day, 250 mg/day, and 375 mg/day.
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Side effects of mesterolone include symptoms of masculinization like acne, scalp hair loss, increased body hair ... at a dosage of 50 to 100 mg 2 to 3 times per day.
(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice ...
Every medication has potential adverse side-effects. With every drug added, there is an additive risk of side-effects. Also, some medications have interactions with other substances, including foods, other medications, and herbal supplements. [46] 15% of older adults are potentially at risk for a major drug-drug interaction. [47]